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Abstract 
Objective: To demonstrate the types of clinical recommendations a pharmacogenomics pharmacist may make to medical clinicians 
with regard to medication management to improve therapeutic outcomes based on varied levels of medical literature evidence. 
Summary: This case demonstrates how a common type of patient seen in a pharmacist practice may present with a varied 
pharmacogenomic (PGx) profile, how they may benefit from PGx analysis, and how varying levels of medical literature evidence can be 
used with clinical decision making. 
Conclusion: PGx testing can help avoid adverse drug reactions (ADRs) or medication inefficacy by assisting in the adjustment of current 
or future medication doses. It can also help predict the best medications to use or those to avoid in advance by eliminating much of the 
existing dosing or medication selection method of trial and error. 
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Introduction 
Pharmacogenomics (PGx) lab testing has become increasingly 
useful in the managing of medications in clinical practice.1 By 
utilizing PGx lab test results, clinicians may now more 
accurately determine how a patient can metabolize certain 
medications to assist in identifying whether a medication will 
not work, work as expected or cause adverse drug reactions 
(ADRs) that may result in increased morbidity or mortality. This 
testing covers genes which control descriptive P-450 enzymes 
or CYP enzymes, primarily located in the small intestine and 
liver and sometimes other genes such as HLA genes. This case 
study will place emphasis on CYP enzymes. CYP enzymes are 
phase I enzymes, responsible for the pharmacokinetic 
metabolism of many common medications. In the past 
nomenclature has been confusing since both the CYP gene and 
the enzyme are called the same name (i.e. CYP2D6). In addition, 
different labs used different terminology for phenotypes, or 
how we actually metabolize drugs, with the same genotype. 
Genotype is how we are genetically programmed to metabolize 
drugs that may or may not be apparent on the surface like a 
phenotype may demonstrate.  
 
PGx testing is usually for multiple genes that control multiple 
medication metabolizing enzymes and proteins, ordered as a 
panel with final results provided in a report. However, clinical 
practice implementation has been slower and more challenging  
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than one may expect. Some explanations for this may be 
differences in testing methods by labs, test selection, cost to 
patients and providers for testing and how to report results 
based on evidence available from PGx labs. In addition, 
clinicians require additional training in the PGx terminology of 
the labs and training on interpretation of results as it applies to 
medication selection and dosing. Other barriers to practice 
implementation are ability of electronic health records (EMRs) 
to store PGx results and how to use and triage clinically 
actionable results to improve care.2-4 To overcome these 
barriers, Mayo Clinic Florida early on vetted and aligned with a 
Clinical Laboratory Improvement Amendments (CLIA) certified 
lab to provide more complete testing for many common PGx 
genes with reporting consistent with the best Clinical 
Pharmacogenetics Implementation Consortium (CPIC) medical 
literature evidence available. This lab also required a health 
care professional to communicate results to patients.5-6 
Experience dictated that the best health care professional to 
review results and make recommendations were medication 
therapy management (MTM) pharmacists. In particular, MTM 
pharmacists specializing in polypharmacy pharmacotherapy 
worked best because of their frequent use of pharmacology in 
their day-to-day practice. In addition, the PGx practice heavily 
uses PharmGKB, a database that sorts and organizes CPIC 
results.1 Clinical annotation levels of PGx evidence range from 
the highest level of medical literature evidence at Level 1A to 
the lowest at Level 4.6 (Figure I) 
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Figure I 
Clinical Annotation Levels of Evidence 
 
 
To overcome the aforementioned PGx challenges at the Mayo 
Clinic Florida, the practice implemented a series of existing 
tools to optimize work flow. PGx patients were integrated into 
the work flow of pharmacotherapy patients with testing having 
been done weeks before to make results available at the time 
of the pharmacist visit. When PGx results are received by the 
lab they are based on available medical literature evidence, 
possible severity of consequences deemed actionable as 
clinically appropriate, then recommendations made. Until EMR 
alerts are fully functional for a gene, highest level evidence and 
actionable gene-drug interactions are listed as allergies with an 
explanation of why they are listed as allergies. Lower level 
evidence, yet possibly clinically relevant gene-drug interactions 
are noted in the pharmacist documentation with provider 
recommendations and the lowest level evidence 
recommendations are suggestions with softer or less definite 
language to match the lower level of evidence of the medical 
literature. Clinical rationale, with references from the medical 
literature is included in all actionable gene-drug interactions 
regarding recommendations or considerations to providers.  
 
It was found important to reference the literature and take into 
consideration levels of evidence in that literature to assist in the 
understanding of recommendations to referring providers who 
were skeptical or unfamiliar with the science of PGx. Education 
of both providers and patients is an important part of using the 
science just as use of PGx should be only by those thoroughly 
familiar with its principles. Not having enough PGx knowledge 
can result in making recommendations and drug selection or 
dose changes exactly opposite of what is intended. This is 
because of some drugs having to be converted as prodrugs to 
the active form to work properly compared to active drugs not 
needing conversion by a CYP enzyme or other protein to an 
active form. 
 
Setting 
The Mayo Clinic Florida practice setting is a multispecialty, 
tertiary care clinic located in Jacksonville, Florida. The clinic 
offers pharmacist-provided medication therapy management 
(MTM), including more advanced PGx services to all patients in 
the clinic via referral from physicians and other providers with 
ordering privileges. The pharmacist PGx service sees patients 
from more than 20 different departments and is considered a 
specialty service, similar to other specialty services within the 
clinic. Practice is an office based practice where pharmacists 
see patients in a provider’s office. 
 
The two primary services performed by the PGx pharmacist are 
focused and comprehensive consults.  PGx pharmacist visits are 
referred to as consults since the service is a consult or specialist 
service and not a longitudinal care service more associated with 
primary care. A focused pharmacist PGx consult is a consult, 
usually face to face, where the pharmacist analyzes a patient’s 
PGx lab results and makes recommendations to the patient and 
provider based on those results only. This is contrary to a 
comprehensive pharmacist PGx consult where a 
comprehensive medication review is included where all Rx, OTC 
medications and dietary supplements are reviewed and not just 
medications relevant to PGx testing.  With some investigational 
study patients, focused consults are performed via phone at the 
convenience of the patient. Focused PGx consults are 30 
minutes; comprehensive consults are 60 minutes in length.  
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The PGx service has its own calendar so all patients scheduled 
have had PGx testing. Scheduling capacity is 15 comprehensive, 
30 focused consults per week or combination of the two types 
of service. OneOme (OO) and Mayo Medical Lab (MML) lab 
panels are used and they test for 27 and 10 genes respectively. 
(Table I) MML only tests for genes with the highest two levels 
of evidence, OO tests for genes of any listed level in PharmGKB.1 
(Table I) 
 
Table I 
Gene Panels 
OneOme Lab Genes Tested 
CYP1A2 CYP2B6 CYP2C9 CYP2C19 CYP2D6 CYP2C19 
CYP2C cluster CYP3A4 CYP3A5 CYP4F2 COMT DPYD 
DRD2 F2 F5 GRIK4 HLA-A HLA-B 
HTR2A HTR2C IFNL4 NUDT15 OPRM1 SLC6A4 
SLOC1B1 TPMT UGT1A1 VCORC1 Source: OneOme13 
Mayo Medical Lab Genes Tested 
CYP1A2 CYP2C cluster* CYP2C9 CYP2C19 CYP2D6 SLOC1B1 
CYP3A4 CYP3A5 CYP4F2 VCORC1 Source: Mayo Medical Labs14 
*CYP2C cluster is referred to as rs12777823 at Mayo Medical Labs 
 
Case Report 
Our subject is a 49 year-old white female with a past medical 
history of renal cell carcinoma, post coronary stent, coronary 
artery disease (CAD), hyperlipidemia, essential hypertension 
and major depression. She did not obtain depression symptom 
relief with lower sertraline dosing so her dose had been 
escalated over time. At the consult the patient reported 
symptoms of fatigue and tachycardia even while taking a beta 
blocker, leg cramping, nausea, GI cramping, myoclonic jerks and 
frequent diaphoresis. She was referred as a PGx investigational 
study patient from urology where she was being treated for her 
renal cell carcinoma. Urology was investigating PGx relevance 
to urology medications. All PGx study patients were referred to 
the PGx pharmacist for a focused PGx consult. Relevant 
medications to her PGx testing and recommendations are 
included in Table II.   
 
Discussion 
PGx test results yielded multiple pharmacist recommendations 
at varied levels of evidence. (Table II) The starred numbers in 
Table II represent the allele or form of a gene from each parent 
divided by a forward slash. 
 
 
Table II 
Pharmacogenomics (PGx) Recommendation Summary 
Drug Daily Dose/Indication Gene Genotype Phenotype Recommendation Evidence Level* 
†Clopidogrel 
 
75 mg 
Once  daily 
Cardiac stent 
CYP2C19 *2/*2 Poor Change 
clopidogrel to 
prasugrel or 
ticagrelor 
1A 
Sertraline 
 
100 mg 
Twice daily 
Depression 
CYP2C19 *2/*2 Poor Change sertraline 
to another 
antidepressant 
1A 
Pantoprazole 
 
40 mg 
Once daily 
Gastroesophageal 
Reflux Disease (GERD) 
CYP2C19 *2/*2 Poor Consider trial 
without or lower 
dose 
3 
Carvedilol 
 
3.125 mg 
Twice daily 
Essential Hypertension 
CYP2D6 (*2A/*9)xN Rapid Consider higher 
dose 
No 
recommendation 
for (*2A/*9)xN 
alleles 
Atorvastatin 
 
80 mg 
Once daily 
Hyperlipidemia 
CYP3A4 *1/*1 Extensive 
(normal) 
No 
recommendation 
3 
†Acutely actionable finding 
*Reference: PharmGKB1 (Figure I) 
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Notably the patient’s results indicated she was phenotypically 
a poor CYP2C19 metabolizer and a rapid CYP2D6 metabolizer. 
Clopidogrel, sertraline and pantoprazole are all CYP2C19 
substrates while carvedilol is primarily a CYP2C9 and CYP2D6 
substrate. Atorvastatin is a CYP3A4 substrate. 
Sertraline and pantoprazole are active agents so poor CYP2C19 
metabolizers would have little to no function of the CYP2C19 
gene resulting in buildup of active drug, higher exposure and 
increased risk of ADRs. Patient reported classic symptoms of 
transient serotonin toxicity and was on a high dose of sertraline. 
When possible cardiovascular (CV) ADRs such as Q-T 
prolongation and past CV medical history were considered 
along with her PGx lab result as a poor CYP2C19 metabolizer, 
recommendation was made to change antidepressants.7-8 
(Table II) Her gastroesophageal reflux disease (GERD) has been 
controlled and she was on a standard dose of pantoprazole. 
Since she may have higher exposure to pantoprazole as a poor 
CYP2C19 metabolizer, a lower dose of pantoprazole was 
suggested if she had to be taking the agent for an extended 
period of time to decrease possible ADRs of 
osteopenia/osteoporosis, renal dysfunction and lower dietary 
mineral or B-12 absorption.9-12 (Table II) 
 
Conversely, clopidogrel is a prodrug and must be converted to 
the active form via CYP2C19 for it to irreversibly bind platelets 
and prevent clotting post-stent placement.6 Therefore, the 
patient, even with clopidogrel treatment, was still at risk for 
clotting and myocardial infarction (MI) because clopidogrel 
would not be converted to the active form and be ineffective as 
a poor CYP2C19 metabolizer. The clopidogrel gene-drug 
interaction was considered actionable because a clot or 
another MI was a possibility at any time. Recommendation was 
made to change clopidogrel to prasugrel or ticagrelor.6 On an 
actionable issue, the clinic referring physician to the PGx service 
is notified through the EMR inbox and the patient is advised to 
speak with the prescribing physician as soon as possible 
regarding the finding during the consult. Mayo Clinic physicians 
are aware of findings faster than referrals outside the clinic 
because of a shared EMR where documentation notes are 
posted in real time. For patients referred from afar outside the 
clinic, it may take longer because the patient is contacting their 
provider.  
 
Carvedilol and CYP2D6 status is unclear. Though some beta 
blockers such as metoprolol are primarily metabolized by 
CYP2D6, carvedilol is metabolized by CYP2C9 and CYP2D6.6 
Patient is a rapid metabolizer of CYP2D6 and extensive (normal) 
metabolizer of CYP2C9. Recommendation to consider a higher 
dose was based on observed tachycardia in this patient and 
seeing a lower-than-target dose of 25 mg twice daily. In 
addition, the current 3.125 mg twice daily dose with a CYP2D6 
rapid metabolizer may create less exposure to the drug, 
resulting in her tachycardia. One could argue the tachycardia 
was a result of higher exposure and high dose of the sertraline, 
and the tachycardia resulted from high serotonin levels.  
Because the patient was an extensive or normal metabolizer of 
CYP3A4 and stable on her atorvastatin, no recommendations 
were made.  
 
Conclusion 
Strength of recommendations can be made based on available 
medical literature evidence of PGx testing to assist with clinical 
decision making. For the same gene, different levels of evidence 
can be found for lab results associated with the different 
medications a patient takes resulting in different clinical 
implications. When using PGx testing with multiple levels of 
literature evidence, more medication recommendations can be 
made. In addition, one can more accurately select medications 
or make medication therapy changes that may result in better 
patient clinical outcomes versus the trial and error method. 
 
In this case, potentially fatal consequences were avoided by 
identifying ineffective therapy in a patient without the ability to 
convert clopidogrel to its active form, possibly resulting in clot 
formation post-stent placement. Patient was recommended to 
take a more effective agent such as prasugrel or ticagrelor. 
Multiple, chronic ADRs, possibly a result of too much serotonin, 
could be eliminated by changing sertraline to an antidepressant 
not metabolized by CYP2C19. Potential dose adjustments were 
identified to decrease potential ADRs in the case of 
pantoprazole and increase efficacy in the case of carvedilol.  
 
Many areas of medicine may benefit from PGx testing and 
interpretation. PGx testing can help avoid ADRs or medication 
inefficacy by assisting in the adjustment of current or future 
new medications or medication doses. It can also help predict 
the best medications to use or those to avoid in advance by 
eliminating much of the existing method of trial and error. 
 
 
 
Abbreviations: ADR = Adverse drug reaction,  CAD = coronary 
artery disease,  CLIA =  Clinical Laboratory Improvement 
Amendments, CPIC =  Clinical Pharmacogenetics 
Implementation Consortium CV = Cardiovascular CYP = 
Cytochrome P450 enzyme,  EMR = electronic medical record,  
MTM = medication therapy management,  PGx = 
Pharmacogenomics,  OTC = Over the counter,  PharmGKB =  
The Pharmacogenomics Database 
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